STAT3 and non-small cell lung carcinoma: Afatinib is mainly used for the treatment of advanced non-small-cell lung cancer, but recent studies have shown that Afatinib can enhance the sensitivity of HCC tumors through signal transducer and activator of transcription 3 (STAT3)/ CD274 molecule (PD-L1) pathway cells with PD-L1 expression, and its combination with anti-PD1 therapy significantly increased the immunotherapeutic efficacy of HCC [25].